Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | NQO2 | P16083 | 3/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578150 | 1.00 | GLA (0.56) | GLACYP1A1CYP1B1CYP1A2NQO2 | |
| SCHEMBL9431599 | 0.73 | CYP1A1 (0.80) | CYP1A1CYP1B1CYP1A2NQO2CYP19A1 | |
| SCHEMBL9586847 | 0.73 | CYP1A1 (0.80) | CYP1A1CYP1B1CYP1A2NQO2CYP19A1 | |
| SCHEMBL5492100 | 0.72 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2NQO2CYP19A1 | |
| SCHEMBL5492093 | 0.72 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2NQO2CYP19A1 | |
| SCHEMBL30442596 | 0.72 | GLA (1.00) | GLACYP1A1CYP1B1CYP1A2NQO2 | |
| SCHEMBL29021873 | 0.72 | GLA (1.00) | GLACYP1A1CYP1B1CYP1A2NQO2 | |
| SCHEMBL9173377 | 0.72 | CYP1A1 (0.84) | CYP1A1CYP1B1CYP1A2NQO2CYP19A1 | |
| SCHEMBL9173364 | 0.72 | CYP1A1 (0.84) | CYP1A1CYP1B1CYP1A2NQO2CYP19A1 | |
| SCHEMBL578014 | 0.71 | L3MBTL1 (0.57) | NQO2ALDH1A1HPGDSMN1; SMN2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2461811-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2417134-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GLA 1607/4885CYP1A1 829/4885CYP1B1 530/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GLA 1607/4885CYP1A1 829/4885CYP1B1 530/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GLA 1607/4885CYP1A1 829/4885CYP1B1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.